Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
A prospective immunogenicity trial of measles and rubella vaccines was conducted in Oman. Children received measles vaccine at age 9 months and measles-rubella vaccine at age 15 months. Serum specimens were tested for measles-specific IgG and rubella-specific IgG. Of 1025 eligible infants, 881 (86.0%) returned for all five visits and had adequate serum samples for testing. Seroconversion to measles after vaccination at 9 months was 98.1%. At 15 months, 47 (5.3%) of the 881 children were seronegative for measles; of these, 44 (93.6%) seroconverted. At 16 months, 99% of the children seronegative at age 9 months seroconverted after receiving two doses of measles vaccine. At age 15 months, 684 (77.6%) children were seronegative for rubella. Of these, 676 (98.8%) seroconverted by age 16 months. One dose of measles vaccine at age 9 months was highly immunogenic. One dose of measles-rubella vaccine at age 15 months closed the remaining measles immunogenicity gap and resulted in a high rate of rubella seroconversion.
Kohler
Kathryn A
KA
Global Immunization Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kik9@cdc.gov
Suleiman
Ali Jaffer M
AJ
Robertson
Susan E
SE
Malankar
Pradeep
P
Al-Khusaiby
Saleh
S
Helfand
Rita F
RF
Brown
David
D
Bellini
William J
WJ
Sutter
Roland W
RW
D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008457:Measles / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage / Q000276:immunology* / Q000592:standards; D009850:Oman / Q000453:epidemiology; D011446:Prospective Studies; D012409:Rubella / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology* / Q000592:standards; D016036:Seroepidemiologic Studies; D017778:Vaccines, Combined / Q000276:immunology / Q000592:standards
D000914:Antibodies, Viral; D008458:Measles Vaccine; D012411:Rubella Vaccine; D017778:Vaccines, Combined